Unlock instant, AI-driven research and patent intelligence for your innovation.

EOC 315 Mod. I crystal form compound and its preparation method

A technology of compound and crystal form, which is applied in the field of pharmaceutical application of EOC315Mod.

Active Publication Date: 2017-09-05
TAIZHOU EOC PHARMA CO LTD
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, no public reports related to the crystal form of EOC315 have been found, and the present invention discloses the Mod.I crystal form of EOC315 for pharmaceutical research for the first time

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • EOC 315 Mod. I crystal form compound and its preparation method
  • EOC 315 Mod. I crystal form compound and its preparation method
  • EOC 315 Mod. I crystal form compound and its preparation method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0066] The preparation of embodiment 1EOC315Mod.I crystal form compound

[0067] The preparation of EOC315Mod.I type crystal compound comprises the following steps:

[0068] 1) Dissolve 9g EOC315 alkali in 90mL methanol to make EOC315 solution, and dissolve 2.5g methanesulfonic acid in 16mL methanol to make methanesulfonic acid solution;

[0069] 2) Start at 50°C, add the methanesulfonic acid solution dropwise into the EOC315 solution, and continue heating for 15 minutes after the drop is complete;

[0070] 3) Distill the filtrate under reduced pressure, evaporate part of the solvent, add 200ml of isopropanol and continue the distillation under reduced pressure until the feed liquid is about 250mL, cool down and crystallize for 1 hour, filter with suction, and collect the filter cake.

[0071] 4) EOC315Mod.I crystal compound was obtained by vacuum drying at 45°C, with a yield of 90.5-96.3% and a purity of 99.1-99.9%.

[0072] Using X-ray diffraction analysis, the figure 1 ...

Embodiment 2

[0073] Example 2 Analysis of the EOC315Mod.I crystal form compound of Example 1 by differential scanning calorimetry (DSC)

[0074] In a nitrogen atmosphere, the DSC trace was recorded on an aluminum plate at a heating rate of 10°C / min. It was measured that EOC315 obtained in Example 1 had a sharp endothermic peak at 200.7°C, indicating that EOC315 was a single Mod.I crystal form with a melting point of 200.7°C. Analytical results such as image 3 .

[0075] Those of ordinary skill in the art know that the measured melting temperature depends on the experimental conditions, especially the heating rate used. Additionally, the melting temperature is affected by the purity of the substance. Reported melting temperatures were determined on products with a purity of at least 98.5%.

Embodiment 3

[0076] Example 3 Analysis of the EOC315Mod.I Crystal Form Compound of Example 1 by X Powder Diffraction

[0077] X-ray powder diffraction data were recorded with germanium-induced monochromatization CuKα1-radiation at room temperature. At room temperature, 2θ scans were performed with an angular resolution of 0.08° between 3°≤2θ≤35° (step size 0.5°) using a small linear position-sensitive detector. X-ray powder diffraction pattern as figure 1 , where 2θ and d(A) values ​​are shown in Table 1.

[0078] Those of ordinary skill in the art will appreciate that the obtained X-ray diffraction patterns may have measurement errors, which errors depend on the measurement conditions. In particular, it is generally known that the intensity of an X-ray diffraction pattern may fluctuate depending on the crystal habit of a substance and the measurement conditions used. In addition, the measurement error of the diffraction angle θ of a conventional X-ray diffraction pattern at a given te...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a preparation method of a Mod.I crystal form compound of 4-(4- chloroaniline)-7-(2- carbonyl methylamino-4-oxygen methyl) pyridyl furan [2, 3-d] pyridazine mesylate (EOC315), a crystal form representation, and a drug application of the compound.

Description

technical field [0001] The invention belongs to the technical field of medicine, and specifically relates to the preparation and characterization of an EOC315Mod.I crystal compound, and also relates to the application of the EOC315Mod.I crystal compound in pharmacy. Background technique [0002] EOC315 (4-(4-Chloroanilino)-7-(2-methylaminocarbonyl-4-oxymethyl)pyridylfuro[2,3-d]pyridazine mesylate) is not currently available in any country listed. ACT Biotech, Inc. (ACTBiotech, hereinafter referred to as ACT), an American biopharmaceutical company, obtained a license for EOC315 from Bayer HealthCare Pharmaceuticals in 2008. In January 2014, Eddington signed an asset purchase agreement with ACT to obtain its global exclusive rights . Its structural formula is as follows: [0003] [0004] EOC315 is an orally bioavailable potent inhibitor of tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2) with an IC50 of 6 nM as measured by biochemical a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D491/048A61K31/5025A61K31/7068A61P35/00
CPCA61K31/5025A61K31/7068C07D491/048C07B2200/13A61K2300/00A61P35/04A61K33/243C07D491/04
Inventor 李合亭王德强常伟于洪瑞邹晓明
Owner TAIZHOU EOC PHARMA CO LTD